Studies Comparing 18F-NaF with Other Radiotracers
Study | Parameter | Sn | Sp | PPV | NPV | Ac |
Meta-analysis of 18F-NaF in both benign and malignant lesions (5) | Patient-based pooled | 96% | 98% | |||
Lesion-based pooled | 97% | 98% | ||||
Bone metastasis detection in hepatocellular carcinoma (37) | 99mTc-MDP | 73.3% | 79.2% | 86.8% | 61.3% | 75.4% |
18F-NaF PET/CT | 93.3% | 100% | 100% | 88.9% | 97.5% | |
Bone metastasis detection in urinary bladder cancer (36) | 99mTc-MDP | 82.35% | 64.51% | 56% | 86.95% | 70.83% |
99mTc-MDP SPECT/CT | 88.23% | 74.19% | 65.21% | 92% | 79.16% | |
18F-NaF PET/CT | 100% | 87.09% | 80.95% | 100% | 91.66% | |
High-risk prostate cancer (35) | 99mTc-MDP | 70% | 57% | 64% | 55% | |
99mTc-MDP SPECT/CT | 92% | 82% | 86% | 90% | ||
18F-NaF PET | 100% | 62% | 74% | 100% | ||
18F-NaF PET/CT | 100% | 100% | 100% | 100% | ||
Spine metastasis in prostate cancer (42) | 99mTc-MDP | 51% | 82% | 86% | 43% | 61% |
18F-NaF PET/CT | 93% | 54% | 82% | 78% | 81% | |
18F-fluoromethylcholine PET/CT | 85% | 91% | 95% | 75% | 87% | |
Bone metastasis detection in head and neck cancer (60) | 18F-NaF PET/CT | 69.4% | ||||
18F-FDG PET/CT | 57.1% | |||||
Detection of skull-base invasion in nasopharyngeal cancer (62) | 18F-NaF PET/CT | 100% | 94.7% | 96.3% | 100% | 97.8% |
18F-FDG PET/CT | 65.4% | 100% | 100% | 67.9% | 80% | |
Detection of bone metastasis in nasopharyngeal cancer (62) | 18F-NaF PET/CT | 98.3% | 65.7% | |||
18F-FDG PET/CT | 42.9% | 97.1% |
Sn = sensitivity; Sp = specificity; PPV = positive predictive value; NPV = negative predictive value; Ac = accuracy.